Forest Labs News

Ironwood Pharmaceuticals filed for an initial public offering today, a move that several biotech investors had previously predicted.

Forest Laboratories is the manufacturer of the thyroid drug Thyrolar, which is the brand name for liotrix, a synthetic T4/T3 combination thyroid hormone replacement drug.

IN PICTURES: 20 Tools For Building Up Your Portfolio It's Not All About Profits Without question, net income matters to a business over the long term.

As usual, inquiries to the folks at Forest Laboratories -- a company that is notoriously unwilling to share information with media, patients and practitioners about the status of their thyroid drugs-- are fruitless.

Educational programming at this meeting is designed to help you enhance your clinical expertise, keep you informed of regulatory issues, and strengthen your business and management skills.

Lonely Value had received cle ar endorsements from 2 billionaires in just the last 48 hours.

Analyst Report ) reported a net loss of 14 cents per share in the third quarter, 6 cents better than the Zacks Consensus Estimate of a net loss of 20 cents.

All News and Columns >>>> Forest Laboratories, Inc. and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products, which require a physician's prescription.

I have written about Forest Laboratories, Inc. before. FRX is a mid-cap player in the biotech and drug markets.

GS_googleAddAdSenseService ; GS_googleEnableAllServices(); GA_googleUseIframeRendering(); _head> _script> NEWS Latest Archives Auto Cells, etc.

Ironwood Pharmaceuticals Inc. and partner Forest Laboratories Inc. reported positive results from two pivotal Phase III trials of its bowel drug candidate linaclotide in chronic constipation.

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced positive top-line results from two Phase 3 clinical trials assessing the safety and efficacy of once-daily dosing of the investigational drug linaclotide in patients with chronic constipation .

On the surface, Mylan 's earnings report wasn't pretty. Revenue fell by 24%, and the company lost $0.13 per share.

This morning, Forest Laboratories, Inc. , reported earnings per share of 85 cents for the second quarter of fiscal 2010, in-line with the Zacks Consensus Estimate.

The Mumbai-based drug firm has settled the matter with Forest Labs and has opted out of the case going on in the district court of Delaware, USA.

Forest Laboratories Inc. on Tuesday said its fiscal second-quarter profit fell 24 percent after it paid $100 million for the rights to market a chronic lung drug candidate.

Pretend you're the CEO of a drug company approaching the dreaded "patent cliff." Products yielding significant sales will soon face generic competition, but you don't know if your home-grown drugs can pick up the slack.

WE BELIEVE THAT Forest Laboratories shares can outperform the market by 15% over the next 12 months, and we are raising our investment rating to Outperform [from Neutral]. Nonconsensus, positive feedback on multiple Forest pipeline drugs from our physician and regulatory consultants at our recent Therapeutic Categories conference improves our ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

Drugmaker Forest Laboratories Inc posted a lower-than-expected quarterly profit on Tuesday and gave an outlook below analysts' forecasts, sending shares down 4.8 percent.